Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | STAT1 | P42224 | 1/20 | 0.40 |
| ▸ | APAF1 | O14727 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RBBP9 | O75884 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 2/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1896858 | 0.87 | LMNA (0.53) | LMNANPC1RAB9AALDH1A1FFAR1 | |
| SCHEMBL1325354 | 0.84 | LMNA (0.51) | LMNANPC1RAB9AALDH1A1FFAR1 | |
| SCHEMBL2772986 | 0.84 | LMNA (0.51) | LMNANPC1RAB9AALDH1A1FFAR1 | |
| SCHEMBL1458950 | 0.83 | LMNA (0.57) | LMNANPC1RAB9AALDH1A1FFAR1 | |
| SCHEMBL28977221 | 0.83 | LMNA (0.48) | LMNANPC1RAB9AALDH1A1FFAR1 | |
| SCHEMBL17439454 | 0.83 | LMNA (0.48) | LMNANPC1RAB9AFFAR1FFAR4 | |
| SCHEMBL27930079 | 0.83 | LMNA (0.50) | LMNANPC1RAB9AALDH1A1FFAR1 | |
| SCHEMBL16402069 | 0.81 | LMNA (0.46) | LMNANPC1RAB9AFFAR1FFAR4 | |
| SCHEMBL18939373 | 0.81 | LMNA (0.55) | LMNANPC1RAB9AALDH1A1FFAR1 | |
| SCHEMBL665075 | 0.80 | LMNA (0.48) | LMNANPC1RAB9AALDH1A1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1286835-C | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents | PHARMACIA ITALIA SPA (IT) | 2006-11-29 | — | — | CN | claimed |
| EP-1724270-A2 | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents | Pfizer Italia S.r.l. (IT) | 2006-11-22 | — | — | EP | claimed |
| EP-1406899-B1 | PHENYLACETAMIDO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2006-11-15 | — | — | EP | claimed |
| US-20040235919-A1 | Phenylacetamido-thiazole derivatives, process for the preparation and their use as antitumor agents | PFIZER ITALIA S.R.I. (IT) | 2004-11-25 | — | — | US | claimed |
| CN-1531535-A | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents | — | 2004-09-22 | — | — | CN | claimed |
| EP-1406899-A2 | PHENYLACETAMIDO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | Pharmacia Italia S.p.A. (IT) | 2004-04-14 | — | — | EP | claimed |
| WO-2003008365-A2 | PHENYLACETAMIDO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA S.P.A. (IT) | 2003-01-30 | — | — | WO | claimed |
| US-20250011330-A1 | Imidazo[1,2- a]pyrazine and Imidazo[1,2- a]pyridine Based Tyrosyl-DNA Phosphodiesterase I (TDP1) Inhibitors | LEIDOS BIOMEDICAL RESEARCH INC. | 2025-01-09 | — | — | US | disclosed |
| CN-103830233-B | 5-(1,2,4-triazol-1-yls) medical usage of-2-phenylacetamido-thiazole | 长沙理工大学 | 2016-08-17 | — | — | CN | disclosed |
| EP-1857108-B1 | PREVENTIVE OR THERAPEUTIC AGENT FOR HERPESVIRUS-RELATED DISEASE | ASTELLAS PHARMA INC (JP) | 2010-12-08 | — | — | EP | disclosed |
| EP-1844775-B1 | THERAPEUTIC AGENT FOR THE TREATMENT OF HERPES PROGENITALIS AFTER DEVELOPMENT OF LESIONS | ASTELLAS PHARMA INC (JP) | 2010-08-11 | — | — | EP | disclosed |
| EP-1844776-B1 | AGENT FOR PREVENTION/TREATMENT OF DISEASE CAUSED BY ACYCLOVIR-RESISTANT HERPESVIRUS | ASTELLAS PHARMA INC (JP) | 2010-04-28 | — | — | EP | disclosed |
| US-20090048310-A1 | AGENT FOR PREVENTION/TREATMENT OF DISEASE CAUSED BY ACYCLOVIR-RESISTANT HERPESVIRUS | ASTELLAS PHARMA INC. (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20040235919-A1 | Phenylacetamido-thiazole derivatives, process for the preparation and their use as antitumor agents | PFIZER ITALIA S.R.I. (IT) | 2004-11-25 | — | — | US | disclosed |
| CN-1531535-A | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents | — | 2004-09-22 | — | — | CN | disclosed |
| CN-1531535-A | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents | — | 2004-09-22 | — | — | CN | disclosed |
| EP-1406899-A2 | PHENYLACETAMIDO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | Pharmacia Italia S.p.A. (IT) | 2004-04-14 | — | — | EP | disclosed |
| US-20040034232-A1 | Amide derivative | ASTELLAS PHARMA INC. (JP) | 2004-02-19 | — | — | US | disclosed |
| EP-1340750-A1 | AMIDE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-09-03 | — | — | EP | disclosed |
| WO-2003008365-A2 | PHENYLACETAMIDO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA S.P.A. (IT) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048310-A1 | AGENT FOR PREVENTION/TREATMENT OF DISEASE CAUSED BY ACYCLOVIR-RESISTANT HERPESVIRUS | ZC3HAV1, ZC3HAV1L, GRIK2 | LMNA 4141/4885NPC1 2398/4885RAB9A 1654/4885 |
| US-20040034232-A1 | Amide derivative | HDAC2, ZC3HAV1, HDAC4 | LMNA 4369/4885NPC1 3690/4885RAB9A 1475/4885 |
| US-20250011330-A1 | Imidazo[1,2- a]pyrazine and Imidazo[1,2- a]pyridine Based Tyrosyl-DNA Phosphodiesterase I (TDP1) Inhibitors | TDP1, TDP2, TOP1 | LMNA 1497/4885NPC1 3699/4885RAB9A 4179/4885 |
| US-20040235919-A1 | Phenylacetamido-thiazole derivatives, process for the preparation and their use as antitumor agents | CDK2, CDK1, CDKN1A | LMNA 3198/4885NPC1 4121/4885RAB9A 2729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.